Enfusion, Inc. (NYSE:ENFN) Short Interest Update

Enfusion, Inc. (NYSE:ENFN - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,010,000 shares, an increase of 41.9% from the January 15th total of 711,700 shares. Based on an average daily trading volume, of 797,400 shares, the short-interest ratio is presently 1.3 days. Approximately 2.4% of the shares of the company are short sold.

Insider Activity at Enfusion

In other news, CEO Oleg Movchan sold 2,771 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the completion of the sale, the chief executive officer now directly owns 526,702 shares of the company's stock, valued at approximately $5,335,491.26. This represents a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Bradley Herring sold 24,443 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the completion of the sale, the chief financial officer now owns 270,503 shares in the company, valued at approximately $2,870,036.83. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 57,367 shares of company stock worth $591,335. 36.44% of the stock is owned by insiders.

Institutional Trading of Enfusion

Institutional investors have recently bought and sold shares of the stock. Centiva Capital LP lifted its holdings in shares of Enfusion by 5.0% during the third quarter. Centiva Capital LP now owns 25,596 shares of the company's stock valued at $243,000 after acquiring an additional 1,227 shares during the period. Harbor Capital Advisors Inc. increased its position in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock worth $113,000 after purchasing an additional 1,315 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Enfusion by 5.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,070 shares of the company's stock valued at $289,000 after purchasing an additional 1,567 shares during the last quarter. Rhumbline Advisers boosted its position in Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company's stock valued at $643,000 after buying an additional 1,796 shares in the last quarter. Finally, Azora Capital LP grew its stake in Enfusion by 6.8% during the third quarter. Azora Capital LP now owns 29,827 shares of the company's stock worth $283,000 after buying an additional 1,890 shares during the last quarter. Institutional investors and hedge funds own 81.05% of the company's stock.

Enfusion Stock Up 1.1 %

ENFN traded up $0.13 during midday trading on Tuesday, reaching $11.13. 542,876 shares of the company's stock were exchanged, compared to its average volume of 1,104,544. The business has a 50-day simple moving average of $10.77 and a two-hundred day simple moving average of $9.59. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of 278.19, a price-to-earnings-growth ratio of 1.83 and a beta of 0.96. Enfusion has a one year low of $7.83 and a one year high of $11.38.

Analyst Ratings Changes

Several research analysts have recently issued reports on ENFN shares. Stifel Nicolaus boosted their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. William Blair restated a "market perform" rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Piper Sandler lifted their price objective on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a report on Monday, December 23rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $10.50.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.